Kezar Life Sciences, Inc.

NasdaqGS:KZR Stock Report

Market Cap: US$60.0m

Kezar Life Sciences Balance Sheet Health

Financial Health criteria checks 5/6

Kezar Life Sciences has a total shareholder equity of $187.6M and total debt of $10.1M, which brings its debt-to-equity ratio to 5.4%. Its total assets and total liabilities are $221.2M and $33.7M respectively.

Key information

5.4%

Debt to equity ratio

US$10.07m

Debt

Interest coverage ration/a
CashUS$201.37m
EquityUS$187.57m
Total liabilitiesUS$33.67m
Total assetsUS$221.24m

Recent financial health updates

Recent updates

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Dec 08
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Oct 03

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Aug 15
Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Aug 11

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Jul 27

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Jul 11

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Jan 03
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Apr 05
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Mar 01
Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Jan 25
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Dec 21
Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

Dec 14

Financial Position Analysis

Short Term Liabilities: KZR's short term assets ($207.0M) exceed its short term liabilities ($17.7M).

Long Term Liabilities: KZR's short term assets ($207.0M) exceed its long term liabilities ($15.9M).


Debt to Equity History and Analysis

Debt Level: KZR has more cash than its total debt.

Reducing Debt: KZR's debt to equity ratio has increased from 0% to 5.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KZR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KZR has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 27.4% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.